Intermittent chemotherapy in metastatic androgen-independent prostate cancer

Tomasz (Tom) Beer, Mark Garzotto, W. D. Henner, K. M. Eilers, E. M. Wersinger

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Intermittent use of chemotherapy for androgen-independent prostate cancer (AIPC) instead of treatment until disease progression may reduce toxicity. We prospectively tested this approach in eight AIPC patients responding to calcitriol plus docetaxel who reached a serum prostate-specific antigen (PSA) -1. Chemotherapy was suspended until a rise in PSA ≥ 50% and 1 ng ml-1. The median duration of treatment holiday was 20 weeks (13-43 + weeks) and all patients retained sensitivity to re-treatment Chemotherapy holiday was associated with an improvement of fatigue (P = 0.05). Intermittent chemotherapy for AIPC is feasible and deserves further study.

Original languageEnglish (US)
Pages (from-to)968-970
Number of pages3
JournalBritish Journal of Cancer
Volume89
Issue number6
DOIs
StatePublished - Sep 15 2003

Fingerprint

Androgens
Prostatic Neoplasms
Drug Therapy
Holidays
docetaxel
Prostate-Specific Antigen
Calcitriol
Fatigue
Disease Progression
Therapeutics
Serum

Keywords

  • Calcitriol
  • Chemotherapy
  • Docetaxel
  • Prostate cancer
  • Vitamin D

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Intermittent chemotherapy in metastatic androgen-independent prostate cancer. / Beer, Tomasz (Tom); Garzotto, Mark; Henner, W. D.; Eilers, K. M.; Wersinger, E. M.

In: British Journal of Cancer, Vol. 89, No. 6, 15.09.2003, p. 968-970.

Research output: Contribution to journalArticle

Beer, Tomasz (Tom) ; Garzotto, Mark ; Henner, W. D. ; Eilers, K. M. ; Wersinger, E. M. / Intermittent chemotherapy in metastatic androgen-independent prostate cancer. In: British Journal of Cancer. 2003 ; Vol. 89, No. 6. pp. 968-970.
@article{eae0a8c74c99467fbe9c336f152b829d,
title = "Intermittent chemotherapy in metastatic androgen-independent prostate cancer",
abstract = "Intermittent use of chemotherapy for androgen-independent prostate cancer (AIPC) instead of treatment until disease progression may reduce toxicity. We prospectively tested this approach in eight AIPC patients responding to calcitriol plus docetaxel who reached a serum prostate-specific antigen (PSA) -1. Chemotherapy was suspended until a rise in PSA ≥ 50{\%} and 1 ng ml-1. The median duration of treatment holiday was 20 weeks (13-43 + weeks) and all patients retained sensitivity to re-treatment Chemotherapy holiday was associated with an improvement of fatigue (P = 0.05). Intermittent chemotherapy for AIPC is feasible and deserves further study.",
keywords = "Calcitriol, Chemotherapy, Docetaxel, Prostate cancer, Vitamin D",
author = "Beer, {Tomasz (Tom)} and Mark Garzotto and Henner, {W. D.} and Eilers, {K. M.} and Wersinger, {E. M.}",
year = "2003",
month = "9",
day = "15",
doi = "10.1038/sj.bjc.6601232",
language = "English (US)",
volume = "89",
pages = "968--970",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Intermittent chemotherapy in metastatic androgen-independent prostate cancer

AU - Beer, Tomasz (Tom)

AU - Garzotto, Mark

AU - Henner, W. D.

AU - Eilers, K. M.

AU - Wersinger, E. M.

PY - 2003/9/15

Y1 - 2003/9/15

N2 - Intermittent use of chemotherapy for androgen-independent prostate cancer (AIPC) instead of treatment until disease progression may reduce toxicity. We prospectively tested this approach in eight AIPC patients responding to calcitriol plus docetaxel who reached a serum prostate-specific antigen (PSA) -1. Chemotherapy was suspended until a rise in PSA ≥ 50% and 1 ng ml-1. The median duration of treatment holiday was 20 weeks (13-43 + weeks) and all patients retained sensitivity to re-treatment Chemotherapy holiday was associated with an improvement of fatigue (P = 0.05). Intermittent chemotherapy for AIPC is feasible and deserves further study.

AB - Intermittent use of chemotherapy for androgen-independent prostate cancer (AIPC) instead of treatment until disease progression may reduce toxicity. We prospectively tested this approach in eight AIPC patients responding to calcitriol plus docetaxel who reached a serum prostate-specific antigen (PSA) -1. Chemotherapy was suspended until a rise in PSA ≥ 50% and 1 ng ml-1. The median duration of treatment holiday was 20 weeks (13-43 + weeks) and all patients retained sensitivity to re-treatment Chemotherapy holiday was associated with an improvement of fatigue (P = 0.05). Intermittent chemotherapy for AIPC is feasible and deserves further study.

KW - Calcitriol

KW - Chemotherapy

KW - Docetaxel

KW - Prostate cancer

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=0141956345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141956345&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6601232

DO - 10.1038/sj.bjc.6601232

M3 - Article

VL - 89

SP - 968

EP - 970

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 6

ER -